


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:00Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407198" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407198</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eid</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">782</journal-id><journal-id journal-id-type="pmc-domain">eid</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407198</article-id><article-id pub-id-type="pmcid-ver">PMC12407198.1</article-id><article-id pub-id-type="pmcaid">12407198</article-id><article-id pub-id-type="pmcaiid">12407198</article-id><article-id pub-id-type="pmid">40867086</article-id><article-id pub-id-type="doi">10.3201/eid3109.250514</article-id><article-id pub-id-type="publisher-id">25-0514</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Linezolid and Meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> Actinomycetoma, India</subject></subj-group></article-categories><title-group><article-title>Linezolid and Meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> Actinomycetoma, India</article-title><alt-title alt-title-type="running-head">Linezolid and Meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> Actinomycetoma, India</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sardana</surname><given-names initials="K">Kabir</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharath</surname><given-names initials="S">Savitha</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sachdeva</surname><given-names initials="S">Soumya</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Das</surname><given-names initials="S">Shukla</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rai</surname><given-names initials="G">Gargi</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singh</surname><given-names initials="PK">Praveen Kumar</given-names></name></contrib><aff>Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital, New Delhi, India (K. Sardana, S. Sharath, S. Sachdeva); University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi (S. Das, G. Rai, P.K. Singh)</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Kabir Sardana, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital, Rm 167, OPD Bldg, New Delhi 110001, India; email: <email xlink:href="article.sardana@gmail.com">article.sardana@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>31</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496169</issue-id><fpage>1863</fpage><lpage>1865</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="25-0514.pdf"/><abstract><p>Treatment of actinomycotic mycetoma with joint involvement is challenging. We present a patient in India with actinomycotic mycetoma who reached complete cure and remission after linezolid and meropenem treatment with a 2-year posttreatment follow-up. Clinicians should use novel drug regimens based on subspecies variations of <italic toggle="yes">Nocardia</italic> and regional drug susceptibility patterns to guide therapy.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>mycetoma</kwd><kwd>bacteria</kwd><kwd>antimicrobial resistance</kwd><kwd>actinomycetoma</kwd><kwd>linezolid</kwd><kwd>meropenem</kwd><kwd>Nocardia otitidiscaviarum</kwd><kwd>refractory</kwd><kwd>relapse</kwd><kwd>treatment</kwd><kwd>sensitivity</kwd><kwd>combination</kwd><kwd>India</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Actinomycotic mycetoma presents as a triad of symptoms: painless swelling, discharging sinuses, and presence of grains. <italic toggle="yes">Nocardia brasiliensis</italic> is commonly implicated (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). Although varied drugs and regimens have been tried, regional variations in antimicrobial drug sensitivities and species should guide therapy (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>). We detail the clinical course of a refractory case caused by <italic toggle="yes">N. otitidiscaviarum</italic> infection in a patient in which complete clinical and radiologic remission was achieved with a combination regimen of linezolid and meropenem co-administered with trimethoprim/sulfamethoxazole. We also examine the role of penems on the basis of existing data.</p><p>In 2019, we saw a 30-year-old man for painless swelling and multiple pus-discharging sinuses in his right knee for 2 years, which was preceded by trauma from a road traffic accident. Actinomycotic mycetoma was diagnosed and treated with trimethoprim/sulfamethoxazole and dapsone for 6 months, which led to remission for 1 year before recurrence. The patient declined amikacin injections and was treated with trimethoprim/sulfamethoxazole (160 mg/800 mg 2&#215;/d) and faropenem (300 mg) for 6 months, which resulted in complete resolution. Recurrence occurred within 10 months of stopping therapy.</p><p>On examination, multiple nodules with overlying sinuses and scanty seropurulent discharge were apparent on the anterior aspect of right knee (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel A). Ultrasonography of the right knee showed a characteristic dot-in-circle sign (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>
<xref rid="F1" ref-type="fig">Figure 1</xref>) that was confirmed by magnetic resonance imaging. A deep incisional skin biopsy specimen from the nodule revealed epidermal hyperkeratosis, parakeratosis, neutrophil exudate, and irregular acanthosis with multiple small grains in superficial dermis rimmed by dense neutrophilic infiltrate, suggestive of Splendore-Hoeppli phenomenon. </p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Anterior right knee of patient treated with linezolid and meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> actinomycetoma, India. A) Multiple nodules with overlying sinuses over right knee. B) Near-complete resolution with subsidence of sinuses and nodules leaving behind scarring after 2 months of treatment with a 21-day cycle of linezolid and meropenem combined with trimethoprim/sulfamethoxazole.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0514-F1.jpg"/></fig><p>The biopsy specimen collected from the nodule on the right knee revealed the presence of gram-positive, thin, branching filaments, suggestive of actinomycetes. Modified Ziehl-Neelsen stain (using 1% sulphuric acid) showed acid-fast, thin, branching, beaded, filamentous bacilli. Blood agar showed growth of colonies 2&#8211;3 mm in size after 72 hours of aerobic incubation that appeared dry, convex, white, and adherent to the medium (<xref rid="F2" ref-type="fig">Figure 2</xref>). On Sabouraud dextrose agar, the colonies were dry and yellowish-orange in color. Subculture and microscopy revealed branching gram-positive rod, and <italic toggle="yes">Nocardia</italic> was confirmed.</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Tissue culture from patient treated with linezolid and meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> actinomycetoma, India. Blood agar culture shows growth of dry, convex, white colonies that are adherent to the medium. Original magnification &#215;200.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0514-F2.jpg"/></fig><p>Sequencing using found on PCR displayed &gt;99% similarity with <italic toggle="yes">N. otitidiscaviarum</italic> sequences deposited in GenBank (accession nos. <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="NR_041874.1">NR_041874.1</ext-link>, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="KM678016.1">KM678016.1</ext-link>, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="OQ034626.1">OQ034626.1</ext-link>) by using BLAST (<ext-link xlink:href="https://blast.ncbi.nlm.nih.gov" ext-link-type="uri">https://blast.ncbi.nlm.nih.gov</ext-link>) (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>). A sensitivity assay using a Sensititre Rapid Growing Mycobacteria RAPMYCOI Plate (Thermo Fisher Scientific, <ext-link xlink:href="https://www.thermofisher.com" ext-link-type="uri">https://www.thermofisher.com</ext-link>) showed sensitivity to sulfamethoxazole, ciprofloxacin, moxifloxacin, cefoxitin, amikacin, doxycycline, linezolid, imipenem, tobramycin, and ceftriaxone.</p><p>A 21-day cycle of intravenous linezolid (600 mg 2&#215;/d) and meropenem (500 mg 3&#215;/d), along with trimethoprim/sulfamethoxazole (160 mg/800 mg 2&#215;/d) led to a decrease in discharge within 3 weeks and substantial clinical improvement within 2 months of treatment (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel B). Trimethoprim/sulfamethoxazole was continued at the same dose for another 10 months and stopped. Residual disease was treated with another cycle of linezolid and meropenem after 10 months. The patient tolerated therapy well and was in remission for 24 months after stopping treatment.</p><p>Actinomycotic mycetoma is primarily caused by <italic toggle="yes">Nocardia</italic>, <italic toggle="yes">Streptomyces</italic>, and <italic toggle="yes">Actinomadura</italic> species, and the highest incidence is reported in India, Asia, Pakistan, and Yemen (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). Of the various <italic toggle="yes">Nocardia</italic> species, <italic toggle="yes">N. otitidiscaviarum</italic> is rarely reported, predominantly affecting immunocompromised hosts (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>), and is an uncommon and unreported cause of mycetoma. A previous study with DNA sequencing of 441 <italic toggle="yes">Nocardia</italic> species reported <italic toggle="yes">N. otitidiscaviarum</italic> in 5.9% of samples (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). Although there are reports of nocardiosis caused by that species (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>), actinomycotic mycetoma has not been reported. The existing drug regimens entail cyclical administration and long durations of therapy, and our aim was to explore the use of penems as monotherapy or in combination to treat actinomycotic mycetoma (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>,<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref><italic toggle="yes">,</italic><xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>), but no previous study has used a combination with linezolid.</p><p>We tried to avoid the use of amikacin because of its side effects. One the basis of sensitivity patterns and previous data (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>), we used a combination of linezolid and meropenem. Although the sensitivity analysis was tested for imipenem, in vitro studies have shown higher activity of meropenem compared with imipenem against <italic toggle="yes">Nocardia</italic> and reflect its clinical efficacy (<xref rid="R8" ref-type="bibr"><italic toggle="yes">8</italic></xref>). Linezolid has also shown in vitro activity against <italic toggle="yes">Actinomadurae</italic> spp. and <italic toggle="yes">Nocardia</italic> spp. in refractory actinomycotic mycetoma (<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>).</p><p>The refractory nature and recurrences in this case could be a consequence of <italic toggle="yes">N. otitidiscaviarum</italic> infection, which is an uncommon cause of actinomycotic mycetoma. The rapid response and long-term remissions make the described regimen suitable and saves inpatient admission costs and repeated admissions that are needed for other regimens (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). Thus, it is useful to collate existent sensitivity data with regional antimicrobial sensitivity for a logical combination regimen, and more data on that combination can determine its widespread applicability in mycetoma caused by <italic toggle="yes">Nocardia</italic> spp. Clinicians should use advances in drug regimens according to subspecies variations of <italic toggle="yes">Nocardia</italic> and regional antibiotic drug susceptibility patterns to guide therapy.</p><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Appendix</title><p>Additional information for linezolid and meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> actinomycetoma.</p></caption><media xlink:href="25-0514-Techapp-s1.pdf" id="d67e250" position="anchor" orientation="portrait"/></supplementary-material></body><back><fn-group><fn fn-type="other"><p><italic toggle="yes">Suggested citation for this article</italic>: Sardana K, Sharath S, Sachdeva S, Das S, Rai G, Singh PK. Linezolid and meropenem for <italic toggle="yes">Nocardia otitidiscaviarum</italic> actinomycetoma, India. Emerg Infect Dis. 2025 Sep [<italic toggle="yes">date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid3109.250514" ext-link-type="uri">https://doi.org/10.3201/eid3109.250514</ext-link></p></fn></fn-group><bio id="d67e263"><p>Dr. Sardana is director professor and head of the dermatology department at Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia hospital. His research interests include infectious diseases, acne, systemic drugs, and the immunopathogenesis of dermatologic disorders.</p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="webpage"><string-name name-style="western"><surname>Reis</surname><given-names>CMS</given-names></string-name>, <string-name name-style="western"><surname>Reis-Filho</surname><given-names>EGM</given-names></string-name>. Mycetomas: an epidemiological, etiological, clinical, laboratory and therapeutic review. An Bras Dermatol. <year>2018</year>;93:8&#8211;18. <pub-id pub-id-type="doi">10.1590/abd1806-4841.20187075</pub-id><pub-id pub-id-type="pmcid">PMC5871356</pub-id><pub-id pub-id-type="pmid">29641691</pub-id></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sardana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chugh</surname><given-names>S</given-names></string-name>. <article-title>Newer therapeutic modalities for actinomycetoma by <italic toggle="yes">Nocardia</italic> species.</article-title><source>Int J Dermatol</source>. <year>2018</year>;<volume>57</volume>:<fpage>e64</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/ijd.14073</pub-id><pub-id pub-id-type="pmid">29920651</pub-id></mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Barry</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>AlShehri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Alguhani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alhijji</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Binkhamis</surname><given-names>K</given-names></string-name>, <etal>et al.</etal><article-title>A fatal case of disseminated nocardiosis due to <italic toggle="yes">Nocardia otitidiscaviarum</italic> resistant to trimethoprim-sulfamethoxazole: case report and literature review.</article-title><source>Ann Clin Microbiol Antimicrob</source>. <year>2022</year>;<volume>21</volume>:<fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/s12941-022-00511-9</pub-id><pub-id pub-id-type="pmid">35578282</pub-id><pub-id pub-id-type="pmcid">PMC9112502</pub-id></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D</given-names></string-name>, <etal>et al.</etal><article-title>Epidemiology and antimicrobial resistance profiles of the <italic toggle="yes">Nocardia</italic> species in China, 2009 to 2021.</article-title><source>Microbiol Spectr</source>. <year>2022</year>;<volume>10</volume>:<elocation-id>e0156021</elocation-id>. <pub-id pub-id-type="doi">10.1128/spectrum.01560-21</pub-id><pub-id pub-id-type="pmid">35234511</pub-id><pub-id pub-id-type="pmcid">PMC9045199</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ameen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arenas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>V&#225;squez del Mercado</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zacarias</surname><given-names>R</given-names></string-name>. <article-title>Efficacy of imipenem therapy for <italic toggle="yes">Nocardia actinomycetomas</italic> refractory to sulfonamides.</article-title><source>J Am Acad Dermatol</source>. <year>2010</year>;<volume>62</volume>:<fpage>239</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2009.06.043</pub-id><pub-id pub-id-type="pmid">20005007</pub-id></mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ameen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vargas</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Arenas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>del Mercado</surname><given-names>EV</given-names></string-name>. <article-title>Successful treatment of <italic toggle="yes">Nocardia actinomycetoma</italic> with meropenem and amikacin combination therapy.</article-title><source>Int J Dermatol</source>. <year>2011</year>;<volume>50</volume>:<fpage>443</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-4632.2010.04748.x</pub-id><pub-id pub-id-type="pmid">21413956</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>. <article-title>Susceptibility profiles of <italic toggle="yes">Nocardia</italic> spp. to antimicrobial and antituberculotic agents detected by a microplate Alamar Blue assay.</article-title><source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>43660</fpage>. <pub-id pub-id-type="doi">10.1038/srep43660</pub-id><pub-id pub-id-type="pmid">28252662</pub-id><pub-id pub-id-type="pmcid">PMC5333629</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lai</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>HL</given-names></string-name>, <etal>et al.</etal><article-title>Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against <italic toggle="yes">Nocardia brasiliensis, Nocardia asteroides</italic> and unusual <italic toggle="yes">Nocardia</italic> species.</article-title><source>J Antimicrob Chemother</source>. <year>2009</year>;<volume>64</volume>:<fpage>73</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkp144</pub-id><pub-id pub-id-type="pmid">19398458</pub-id></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sardana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sachdeva</surname><given-names>S</given-names></string-name>. <article-title>A combination of trimethoprim/sulfamethoxazole with linezolid is useful for actinomycotic mycetoma: A summary of the existing data and the rationale of combination therapy.</article-title><source>Indian J Dermatol Venereol Leprol</source>. <year>2022</year>;<volume>88</volume>:<fpage>212</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.25259/IJDVL_539_2021</pub-id><pub-id pub-id-type="pmid">34877844</pub-id></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Verma</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jha</surname><given-names>A</given-names></string-name>. <article-title>Mycetoma: reviewing a neglected disease.</article-title><source>Clin Exp Dermatol</source>. <year>2019</year>;<volume>44</volume>:<fpage>123</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/ced.13642</pub-id><pub-id pub-id-type="pmid">29808607</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>